ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
2 announcements with these filters
Bajaj Healthcare received DCGI approval to manufacture and market Cenobamate API and tablets across six strengths in India. This adds a new product to its portfolio.
Bajaj Healthcare received SEC-CDSCO recommendation to manufacture and market Cenobamate Tablets. This regulatory milestone supports the company's growth in the specialty pharmaceuticals segment.